Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Target Price at $79.00

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $79.75.

A number of research firms recently issued reports on ANIP. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock worth $191,776 in the last ninety days. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ANIP. US Bancorp DE lifted its stake in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the last quarter. KBC Group NV lifted its position in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $166,000. Finally, HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals in the third quarter valued at about $222,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Down 0.2 %

Shares of ANIP opened at $64.22 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81. The stock’s 50 day moving average is $58.79 and its two-hundred day moving average is $58.07. The firm has a market cap of $1.40 billion, a P/E ratio of -116.76 and a beta of 0.63.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.